
Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy.



